Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have received a consensus rating of “Buy” from the eight brokerages that are presently covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $23.67.

A number of brokerages have recently issued reports on ACRV. BMO Capital Markets cut their target price on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. KeyCorp began coverage on shares of Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating on the stock. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Acrivon Therapeutics in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald began coverage on shares of Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating on the stock.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of institutional investors have recently modified their holdings of ACRV. China Universal Asset Management Co. Ltd. bought a new stake in shares of Acrivon Therapeutics during the 4th quarter valued at about $40,000. Corton Capital Inc. bought a new stake in shares of Acrivon Therapeutics during the 4th quarter valued at about $73,000. American Century Companies Inc. grew its position in Acrivon Therapeutics by 14.2% in the 4th quarter. American Century Companies Inc. now owns 17,588 shares of the company’s stock worth $106,000 after purchasing an additional 2,186 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Acrivon Therapeutics by 20.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company’s stock worth $223,000 after purchasing an additional 6,239 shares during the last quarter. Finally, Barclays PLC grew its position in Acrivon Therapeutics by 14.4% in the 4th quarter. Barclays PLC now owns 38,091 shares of the company’s stock worth $228,000 after purchasing an additional 4,785 shares during the last quarter. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Stock Performance

Shares of Acrivon Therapeutics stock opened at $5.29 on Tuesday. The firm has a market cap of $164.71 million, a PE ratio of -1.96 and a beta of 0.85. The firm’s 50-day simple moving average is $5.68 and its 200-day simple moving average is $6.91. Acrivon Therapeutics has a 1 year low of $4.49 and a 1 year high of $11.90.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.